Biopsies are usually performed with the suspicion of DA already formulated to exclude other diagnoses that may account for the clinical appearance. The histological findings include sharply delineated areas of ulceration or vesiculation, "mummified" pattern of epidermal necrosis frequently associated with sparing of the adnexa, lack of significant dermal inflammation, and localized areas of dermal hemorrhage. [3] In 2013, Winters et al. added epidermal multinucleated keratinocytes to the histopathologic spectrum of DA. [4] During the following years, Gutierrez et al., Amin et al., and Sweeney et al. independently reported additional cases establishing the link between multinucleated epidermal keratinocytes and DA. [5] [6] [7] The multinucleated keratinocytes are present at various levels of the epidermis and may contain up to 20 nuclei. The nuclei vary from large and vesicular with prominent nucleoli to small, pyknotic, and mummified in appearance [ Figure 1a -c]. [5] [6] [7] Awareness of this phenomenon is particularly important in the setting of blistering lesions of DA, where they may be confused with epidermal keratinocytes infected by herpesvirus. In contrast to those in herpesvirus infection, the multinucleated keratinocytes in DA have a larger number of nuclei which lack nuclear molding or margination of chromatin.
It has been postulated that damaged, dyskeratotic tonofilaments may interfere with the mitotic apparatus preventing cell division and thereby leading to multinucleation. [5] Grover dIsease -newer varIants Grover disease is a common pruritic papulovesicular pruritic eruption of unknown etiology that was first described in 1970 by Grover. [8] It predominantly affects the sun-damaged skin of the trunk and proximal extremities in middle-aged or elderly Caucasian men. Despite the synonym "transient acantholytic dyskeratosis," persistent pruritic and chronic asymptomatic forms of Grover disease are also known to occur. [9] The histopathologic hallmark of Grover disease is acantholysis accompanied by a superficial perivascular lymphocytic infiltrate, often with admixed eosinophils. Four distinct histopathologic patterns are commonly recognized: Darier-like, pemphigus vulgaris-like, Hailey-Hailey-like, and spongiotic. Commonly, these patterns coexist which serve as a useful diagnostic clue. [10] It was not until 2010 that the histopathologic variation of Grover disease was critically reappraised by Fernández-Figueras et al. [11] This group reviewed 120 archival cases of Grover disease (having at least one of the conventional patterns) and identified five additional histologic patterns: porokeratotic, lentiginous, vesicular, lichenoid, and dysmaturative. In the porokeratotic form, there are cornoid lamellae with associated hypogranulosis and basal vacuolization [ Figure 2a ]. Lentiginous Grover disease is characterized by elongated rete ridges with basal hyperpigmentation and acantholysis affecting the stratum basalis or superficial layers of the epidermis [ Figure 2b ]. In the vesicular variant, there is intraepidermal vesiculation with acantholysis [ Figure 2c ]. The lichenoid pattern is characterized by mild lymphocytic inflammation at the dermoepidermal junction with subtle acantholysis. The dysmaturative form features disordered keratinocyte maturation with nuclear pleomorphism and mild hyperchromasia in addition to acantholysis. In 2013, Wiersma et al. alluded to a pseudoherpetic variant where the acantholytic cells may be potentially mistaken for herpesvirus-infected epidermal cells because of keratinocyte multinucleation and dyskeratosis [ Figure 2d ]. Unlike herpesvirus infection, acantholytic cells in Grover disease are generally localized to the suprabasal epidermis and lack nuclear molding. [12] This broadening of the histopathologic spectrum significantly expands the scenarios in which Grover disease needs to be considered in the differential diagnosis. It should be pointed out that irrespective of these newly described variants, acantholysis and the presence of a dermal lymphocytic infiltrate usually accompanied by eosinophils remain the bedrock for histopathologic diagnosis of Grover disease.
eosInophIlIc annular erythema
The existence and nosologic position of eosinophilic annular erythema (EAE) has been steeped in controversy. It was first described in 1999 by Kahofer et al., who were struck by a morphologically gyrate erythematous rash histologically characterized by an eosinophil-rich perivascular lymphocytic infiltrate [ Figure 3a and b]. [13] Since the original description of EAE, there has been considerable debate surrounding its relationship with eosinophilic cellulitis (Wells syndrome).
Like eosinophilic cellulitis, EAE shows a marked angiocentric eosinophil-rich infiltrate, but flame figures and granulomatous inflammation were conspicuously lacking. Clinically, it usually does not show prodromal symptoms or edema, lacks a relapsing and remitting course, and neither does it result in morphea-like areas upon resolution. [14] Subsequent authors have sometimes considered EAE as a variant of eosinophilic cellulitis. Rongioletti et al. described two patients with clinicopathologic features consistent with the original description of EAE but with the addition of flame figures and surrounding granulomatous inflammation. [15] They postulated that EAE was a clinical subset of eosinophilic cellulitis presenting with an annular or figurate pattern.
In 2013, El-Khalawany et al. reported a prospective multicenter study of 10 patients diagnosed with EAE, the largest case series published to date. [16] Biopsies performed at varying stages of lesional evolution showed a spectrum of histopathologic changes. They found that early, minimally edematous, plaques contained a dense dermal eosinophilic infiltrate, some of which had degranulated and were accompanied by a small quantity of lymphocytes and histiocytes. Well-developed figurate or annular lesions in comparison exhibited a mixed infiltrate of histiocytes and eosinophils. There was papillary dermal edema in the majority of cases. Flame figures with surrounding multinucleated giant cells were easily identified in long-standing cases. They observed that aggressive immunosuppression even in combination regimens had little clinical impact and suggested that EAE was a particularly chronic and treatment-resistant variant of eosinophilic cellulitis. [16] monoGenIc autoInflammatory dIseases
Monogenic autoinflammatory diseases (MADs) are a group of hyperinflammatory conditions caused by single-gene mutations involving innate immune regulatory pathways. They are characterized by unprovoked recurrent attacks of sterile systemic inflammatory episodes that result in fever, rashes, joint pain, and features of disease-specific organ inflammation mimicking infection or sepsis. [17] The pathogenesis of MAD involves gain of function mutations affecting interleukin-1 (IL-1) and IL-18 activating inflammasomes. [18] These disorders gained wider recognition following the discovery of mutations underpinning familial Mediterranean fever (FMF) and tumor necrosis factor-receptor-associated periodic syndrome (TRAPS) in 1997 and 1999, respectively. [19, 20] In defining the autoinflammatory phenotype, McDermott et al. considered cutaneous inflammation as a prominent feature which waxes and wanes with fluctuating disease activity, often resolving completely between flares. [20] In recent years, attempts have been made to group MAD based on easily identifiable clinical criteria that can be elicited from a patient's history, physical examination, fever patterns, skin lesions, and associated clinical findings. The following six clinical groups have been proposed: (1) nonspecific maculopapular rash/classic "periodic fever syndromes," for example, FMF and TRAPS; (2) neutrophilic urticaria/cryopyrinopathies, for example, Muckle-Wells syndrome; (3) granulomatous skin lesions and minimal or low-grade fever attacks, for example, Blau syndrome/early-onset sarcoidosis; (4) pustular skin rashes and episodic fever, for example, deficiency of IL-1 receptor antagonist, Majeed syndrome, pyogenic arthritis, pyoderma gangrenosum, and acne syndrome; (5) atypical neutrophilic dermatosis with histiocytic-like infiltrate, for example, proteasome-associated autoinflammatory syndromes; and (6) syndromes with autoinflammation and immunodeficiency. [21] Given the rarity, myriad of clinical presentation, and the requirement of extensive genetic testing to establish the diagnosis, it is not surprising that the histopathologic characteristics of individual MAD are yet to be elucidated in detail. A shared histopathologic feature which seems common to many MAD is the presence of perivascular and interstitial infiltrate comprising neutrophils [ Figure 4 ] and/or lymphocytes [ Figure 5 ]. Some interesting insights linking the pathogenetic mechanisms and histopathologic presentation have come to light in recent years. IL-1-mediated MAD often presents with neutrophilic urticaria, perivascular lymphocytic/ monocytic infiltrate, and pustulosis. On the other hand, interferon-mediated disorders tend to feature vasculitis, livedo reticularis, and panniculitis. [17] It must be pointed out that our understanding of MAD is still evolving. Awareness of these conditions among dermatopathologists is nevertheless very important for several reasons. It is hoped that in the near future, a clearer understanding of the microscopic features of individual MAD will assist in targeted genetic testing. Early diagnosis and prompt appropriate treatment is critical in preventing organ damage and life-threatening complications. From a therapeutic perspective, it is important to be aware that many of the MADs show an excellent response to IL-1-blocking agents.
sweet syndrome -newer varIants
Sweet syndrome, the prototypic neutrophilic dermatosis, was first described in 1964. [22] It is characterized by a constellation of clinical symptoms, physical features, and histopathologic findings which include fever, neutrophilia, tender erythematous skin lesions (papules, nodules, and plaques), and a diffuse infiltrate consisting predominantly of mature neutrophils that are typically located in the upper dermis. The lesions have a propensity to affect the face, neck, and upper extremities. Sweet syndrome can present in three different clinical settings: classical (or idiopathic), malignancy associated, and drug induced. [23, 24] The diagnostic criteria for Sweet syndrome were originally proposed by Su and Liu in 1986 [25] and subsequently modified by von den Driesch in 1994. [26] Both schemes require diffuse infiltrate of mature neutrophils as a major criterion. In addition to a dense, diffuse dermal infiltrate of neutrophils in the upper dermis, there is prominent papillary dermal edema. Some cases show neutrophilic exocytosis with formation of neutrophilic spongiotic vesicles or subcorneal pustules.
Vasculitic changes, seen in some cases of Sweet syndrome, are believed to be secondary rather than primary in nature.
Resolving lesions often contain a large number of histiocytes and those comprised almost entirely of histiocytoid myeloid precursors are designated as "histiocytoid Sweet." [27] Similarly, variants with a predominance of eosinophils or lymphocytes have also been reported. [28, 29] The neutrophilic infiltrate of Sweet syndrome is usually localized within the papillary and upper reticular dermis. Two recently described variants are worthy of mention, as they are characterized by an unusually deep extension of the inflammation. In the subcutaneous variant, the infiltrate is confined to the subcutaneous fat (usually as a lobular panniculitis) with sparing of the dermis. The latter often shows edema and reactive fibroblastic proliferation. The subcutaneous variant of Sweet needs to be histologically distinguished from other neutrophilic panniculitis, for example, early erythema nodosum, infectious panniculitis, panniculitic id reaction, and leukemia cutis. Distinction between subcutaneous Sweet syndrome and early erythema nodosum can be particularly vexing. It is useful to be aware that Miescher's radial granuloma, a useful clue for erythema nodosum, can also be seen in subcutaneous Sweet syndrome [ Figure 6a and b].
Since erythema nodosum tends to respond to nonsteroidal anti-inflammatory drugs (NSAID), it has been proposed that a trial of NSAID is an effective way of distinguishing the two entities in problematic cases. [30] Kroshinsky and Fairley described an additional necrotizing variant of Sweet syndrome in immunosuppressed patients who presented with a rapidly expanding solitary erythematous plaque clinically mistaken for necrotizing fasciitis. The histopathologic features on the surgical debridement specimens closely mimicked necrotizing fasciitis, i.e., widespread acute necrotizing neutrophilic dermatosis involving the skin, subcutaneous fat, fascia, and skeletal muscle but persistently negative cultures and special stains for microorganisms [ Figure 7a and b]. A lack of improvement following surgery and antibiotic therapy, signs of pathergy at the sites of surgical intervention, and an excellent response to steroids are useful clues for necrotizing Sweet syndrome. Awareness of this unusual variant is critical for both dermatologists and plastic surgeons so that the vicious cycle of debridement and pathergic expansion of the process with significant morbidity can be avoided. [31] reactIve Granulomatous dermatItIs
The term "reactive granulomatous dermatitis" (RGD) has been recently coined by Rosenbach and English to encompass a complex group of interstitial granulomatous dermatitides (IGDs) which share overlapping clinicopathologic features and therapeutic options. [32] The group includes IGD, palisaded and neutrophilic granulomatous dermatitis (PNGD), and interstitial granulomatous drug reaction (IGDR), conditions with substantial clinical, histopathologic, and therapeutic overlap.
IGD (synonym IGD with arthritis) was first described in 1993 by Ackerman in patients presenting with a linear, cord-like configuration ("rope sign") developing in the setting of inflammatory arthritis. [33] Other triggers include hematological malignancies and medications. Although linear cord-like lesions are virtually pathognomonic, the clinical spectrum of IGD has been expanded to include erythematous macules, skin colored or erythematous papules, plaques, and nodules, predominantly involving the extremities of middle-aged females. Histologically, there is an interstitial infiltrate of histiocytes, centered in the deeper dermis often surrounding degenerate collagen fibers [ Figure 8a and b]. Mucin deposition is scant to absent. [34] PNGD, first described in 1994 by Chu et al., refers to a papular eruption of the extremities in association with connective tissue diseases. [35] There is a significant clinical overlap between PNGD and IGD in terms of female predominance, age range, and lesional morphology. Histopathologically, PNGD shows a spectrum of changes reflecting stages of evolution of the lesions. Early lesions are characterized by dense neutrophilic infiltrate, leukocytoclastic vasculitis, and altered collagen. Established lesions feature palisading granulomas surrounding leukocytoclastic debris, fibrin, and necrobiosis [ Figure 9a and b]. Dermal fibrosis and palisading granulomas predominate, while neutrophils are sparse in late lesions. [35, 36] IGDR deserves specific mention, as it is often poorly defined in the medical literature. It presents with lesions of varying morphology usually affecting the proximal extremities and occasionally the trunk. Histopathologic features overlap with IGD, but useful distinguishing features include vacuolar interface changes, presence of dermal eosinophils, and inconspicuous necrobiosis. [34, 37] Given the overlapping clinical and histopathologic features, similarities in disease associations, and treatment strategies, it makes conceptual sense to use the unifying term RGD and simply identifying the underlying trigger rather than trying to fit them rigidly under IGD, PNGD, or IGDR. [32] postIrradIatIon morphea
Postirradiation morphea (PIM) is a rare complication of radiation therapy which is increasingly being encountered in breast cancers patients treated with radiation therapy. First described in 1989 by Colver et al., less than 100 cases have been reported although the incidence appears to be rising due to the increasing emphasis on a breast-sparing approach and postoperative radiation therapy for treatment of breast cancers. It is estimated that PIM affects 0.2% of breast cancer patients undergoing radiation therapy. [38, 39] The interval between radiation exposure and the development of PIM is highly variable and ranges from 1 month to 32 years. [40] The clinical presentation is dependent of the stage of the disease and varies from erythematous and edematous plaques (early inflammatory) to induration, violaceous discoloration, and peau d'orange appearance of the affected area (advanced sclerotic).
There is no clear relationship between the total radiotherapy dose, fractionation scheme, use of a boost, and the incidence of PIM. It is often clinically confused with locally recurrent carcinoma, radiation dermatitis, postirradiation atypical vascular proliferation, and cellulitis, prompting a skin biopsy. Unlike some of the other postirradiation dermatoses, PIM can sometimes extend beyond the area of prior irradiation.
Indistinguishable histologically from conventional morphea, PIM progresses from an early inflammatory, intermediate to a late sclerotic stage. In the early inflammatory stage, there is an interstitial and perivascular lymphoplasmacytic with subtle collagen thickening [ Figure 10a ]. The intermediate stage features a lymphoplasmacytic infiltrate in the subcutaneous fat and around the eccrine gland coils along with thickening of the collagen bundles. In the late sclerotic stage, the reticular dermal collagen is swollen and hypocellular, inflammation is either sparse or absent, adnexal structures are lost, and there is replacement of the subcutaneous fat by sclerotic collagen [ Figure 10b ]. [41] A skin biopsy plays a vital role in distinguishing PIM from several other postirradiation disorders which may appear clinically similar. This includes acute radiation dermatitis (keratinocyte apoptosis, vasodilation with fibrin thrombi, and erythrocyte extravasation), subacute radiation dermatitis (interface dermatitis with satellite cell necrosis mimicking acute graft vs. host disease), and chronic radiation dermatitis (hyperkeratosis, acanthosis, and advanced sclerosis with bizarre "atypical" fibroblasts). Distinction of PIM and chronic radiation dermatitis can be problematic. PIM tends to show more inflammation, the fibrosis is centered in the dermis and the changes frequently extend beyond the radiation field. [39] In comparison, chronic radiation dermatitis lacks inflammation and fibrotic changes primarily affect the subcutaneous fat and are limited to the radiation field. [41] Awareness and prompt recognition of PIM is very important as a range of treatment options are available which can favorably modify the disease course and prevent disfiguring lesions, especially if instituted early.
nonuremIc calcIphylaxIs
Calciphylaxis is a rare and life-threatening form of metastatic calcification occurring primarily but not exclusively in the setting of end-stage renal disease and secondary hyperparathyroidism. Calciphylaxis arising in a "nontraditional setting," i.e., without end-stage renal disease (nonuremic calciphylaxis) is rare but is being increasingly recognized. Interestingly, although the term "calciphylaxis" was proposed in 1961 by Selye et al. through pioneering animal experiments, [42] the first reported cases which could fit the operational definition of nonuremic calciphylaxis can be traced 5 years prior in a study by Bogdonoff et al. [43] Conditions known to be associated with nonuremic calciphylaxis include primary hyperparathyroidism, malignancies, alcoholic liver disease, connective tissue diseases, diabetes, chemotherapy-induced protein C and S deficiency, Crohn's disease, monoclonal gammopathies, Vitamin D deficiency, obesity, rapid weight loss, thrombophilia, and steroid or warfarin use. [44, 45] The clinicopathologic features of conventional and nonuremic calciphylaxis are identical and characterized by vascular calcification and cutaneous necrosis. Clinically, calciphylaxis presents with painful erythematous macules and plaques on adipose-rich areas which progress to retiform purpura and eventual necrosis and ulceration. There may be subtle subcutaneous induration extending beyond the visible surface lesions. [46] Histopathologic features of calciphylaxis include small vessel mural calcification, intimal proliferation, and luminal thrombosis [ Figure 11a ]. Vascular calcification is not pathognomonic of calciphylaxis, and in particular, medium vessel calcification is common in patients with renal failure on hemodialysis. A number of other histopathologic features which may serve as useful clues in the appropriate clinical context include dermal ulceration, dermal-epidermal separation, dermal angiomatosis, lobular panniculitis, and fat necrosis. [47, 48] A few relatively recent observations merit particular mention due to their usefulness in refining the histopathologic diagnosis of calciphylaxis. Subtle and stippled calcium deposits in the basement membrane surrounding eccrine coils (perieccrine calcification) and internal elastic lamina have been found to be useful in cases where vascular calcification is not obvious [ Figure 11b and c]. [49] Pseudoxanthoma elasticum-like fragmentation and calcification of elastic fibers in the dermis have been noted in biopsies from calciphylaxis (including nonuremic form). [50] The pathogenesis of calciphylaxis is poorly understood but is likely to be multifactorial involving dysregulation of calcium, phosphate, parathyroid hormone, and coagulation. In nonuremic cases, derangements in the function of receptor activator of NF-κB ligand and osteoprotegerin are suspected to play a contributory role. [51] conclusIon The spectrum of known inflammatory skin disorders is constantly evolving. With ever closer clinicopathologic correlation, new entities and additional variants of established conditions are being revealed. While the advent of the genomic era is set to revolutionize tumor diagnosis, the ability of the dermatopathologist to engage with their clinical colleagues and maintain an up to date knowledge base remains key to accurate histopathologic interpretation and diagnosis in inflammatory skin diseases.
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